Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

A Narrative Review of Implementing Precision Oncology in Metastatic Castration-Resistant Prostate Cancer in Emerging Countries

A Narrative Review of Implementing Precision Oncology in Metastatic Castration-Resistant Prostate... The therapeutic landscape of metastatic castration-resistant prostate cancer (mCRPC) has evolved considerably with the introduction of newer agents, such as poly-ADP ribose polymerase (PARP) inhibitors targeting DNA damage repair mutations. Combining and sequencing novel and existing therapies appropriately is necessary for optimizing the management of mCRPC and ensuring better treatment outcomes. The purpose of this review is to provide evidence-based answers to key clinical questions on treatment selection, treatment sequencing patterns, and factors influencing treatment decisions in the management of mCRPC in the era of PARP inhibitors. This article can also serve as a comprehensive guide to clinicians for optimizing genetic testing and counseling and management of patients with mCRPC. Although the PROfound study has validated the concept of PARP sensitivity across multiple genes associated with homologous recombination repair (HRR) in mCRPC and highlighted the importance of genomic testing in this at-risk patient population, it still remains unclear how patients with rarer HRR mutations will respond to PARP inhibitors. Therefore, real-world data obtained through registry-based randomized controlled trials in the future may help produce robust scientific evidence for supporting optimal clinician decision-making in the management of mCRPC. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Oncology and Therapy Springer Journals

A Narrative Review of Implementing Precision Oncology in Metastatic Castration-Resistant Prostate Cancer in Emerging Countries

Download PDF
17 pages

Loading next page...
 
/lp/springer-journals/a-narrative-review-of-implementing-precision-oncology-in-metastatic-6uEuBzshsk
Publisher
Springer Journals
Copyright
Copyright © The Author(s) 2021
ISSN
2366-1070
eISSN
2366-1089
DOI
10.1007/s40487-021-00160-6
Publisher site
See Article on Publisher Site

Abstract

The therapeutic landscape of metastatic castration-resistant prostate cancer (mCRPC) has evolved considerably with the introduction of newer agents, such as poly-ADP ribose polymerase (PARP) inhibitors targeting DNA damage repair mutations. Combining and sequencing novel and existing therapies appropriately is necessary for optimizing the management of mCRPC and ensuring better treatment outcomes. The purpose of this review is to provide evidence-based answers to key clinical questions on treatment selection, treatment sequencing patterns, and factors influencing treatment decisions in the management of mCRPC in the era of PARP inhibitors. This article can also serve as a comprehensive guide to clinicians for optimizing genetic testing and counseling and management of patients with mCRPC. Although the PROfound study has validated the concept of PARP sensitivity across multiple genes associated with homologous recombination repair (HRR) in mCRPC and highlighted the importance of genomic testing in this at-risk patient population, it still remains unclear how patients with rarer HRR mutations will respond to PARP inhibitors. Therefore, real-world data obtained through registry-based randomized controlled trials in the future may help produce robust scientific evidence for supporting optimal clinician decision-making in the management of mCRPC.

Journal

Oncology and Therapy – Springer Journals

Published: Dec 1, 2021

Keywords: Castration-resistant; Genetic testing; Metastasis; PARP inhibitors; PROfound study; Prostate cancer

References

  • Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
    Sung, H; Ferlay, J; Siegel, RL
  • The natural history of metastatic progression in men with prostate-specific antigen recurrence after radical prostatectomy: long-term follow-up
    Antonarakis, ES; Feng, Z; Trock, BJ
  • Navigating the evolving therapeutic landscape in advanced prostate cancer
    Crawford, ED; Petrylak, D; Sartor, O
  • Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points
    Tannock, IF; Osoba, D; Stockler, MR
  • Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study
    Kantoff, PW; Halabi, S; Conaway, M
  • Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer
    Tannock, IF; Wit, RD; Berry, WR
  • Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer
    Petrylak, DP; Tangen, CM; Hussain, MHA
  • Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial
    De Bono, JS; Oudard, S; Ozguroglu, M
  • The androgen receptor and VEGF: mechanisms of androgen-regulated angiogenesis in prostate cancer
    Eisermann, K; Fraizer, G
  • Maximum androgen blockade in advanced prostate cancer: a meta-analysis of published randomized controlled trials using nonsteroidal antiandrogens
    Caubet, JF; Tosteson, TD; Dong, EW
  • Abiraterone and increased survival in metastatic prostate cancer
    De Bono, JS; Logothetis, CJ; Molina, A
  • Abiraterone in metastatic prostate cancer without previous chemotherapy
    Ryan, CJ; Smith, MR; de Bono, JS
  • Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study
    Ryan, CJ; Smith, MR; Fizazi, K
  • Enzalutamide in metastatic prostate cancer before chemotherapy
    Beer, TM; Armstrong, AJ; Rathkopf, DE
  • Increased survival with enzalutamide in prostate cancer after chemotherapy
    Scher, HI; Fizazi, K; Saad, F
  • Safety and antitumor activity of apalutamide (ARN-509) in metastatic castration-resistant prostate cancer with and without prior abiraterone acetate and prednisone
    Rathkopf, DE; Antonarakis, ES; Shore, ND
  • Sipuleucel-T immunotherapy for castration-resistant prostate cancer
    Kantoff, P; Paszulewicz, A; Holko, P; Pilc, A
  • Alpha emitter radium-223 and survival in metastatic prostate cancer
    Parker, C; Nilsson, S; Heinrich, D
  • Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trial
    Sartor, O; Coleman, R; Nilsson, S
  • An observational study of concomitant use of emerging therapies and denosumab or zoledronic acid in prostate cancer
    Liede, A; Wade, S; Lethan, J
  • Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer
  • Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study
    Fizazi, K; Carducci, M; Smith, M
  • Exploring the optimal sequence of abiraterone and enzalutamide in patients with chemotherapy-naïve castration-resistant prostate cancer: the Kyoto-Baltimore collaboration
    Terada, N; Maughan, BL; Akamatsu, S
  • Impact of treatment sequence in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): data from the prospective PROREPAIR-B study
    Cattrini, C; Laorden, NR; Castro, E
  • The effect of treatment sequence on overall survival for men with metastatic castration-resistant prostate cancer: a multicenter retrospective study
    Okita, K; Hatakeyama, S; Narita, S
  • Cabazitaxel versus abiraterone or enzalutamide in metastatic prostate cancer
    de Wit, R; de Bono, J; Sternberg, CN
  • Precision medicine applications in prostate cancer
    McCrea, EM; Lee, DK; Sissung, TM; Figg, WD
  • The heritability of prostate cancer in the Nordic Twin study of cancer
    Hjelmborg, JB; Scheike, T; Holst, K
  • Targeted next-generation sequencing of advanced prostate cancer identifies potential therapeutic targets and disease heterogeneity
    Beltran, H; Yelensky, R; Frampton, GM
  • Integrative clinical genomics of advanced prostate cancer
    Robinson, D; Van Allen, EM; Yi-Mi, Wu
  • Inherited DNA-repair gene mutations in men with metastatic prostate cancer
    Pritchard, CC; Mateo, J; Walsh, MF
  • Prospective genomic profiling of prostate cancer across disease states reveals germline and somatic alterations that may affect clinical decision making
    Abida, W; Armenia, J; Gopalan, A
  • Germline BRCA1 mutations increase prostate cancer risk
  • BRCA2 is a moderate penetrance gene contributing to young-onset prostate cancer: implications for genetic testing in prostate cancer patients
    Kote-Jarai, Z; Leongamornlert, D; Saunders, E
  • Biomarkers of response and resistance to DNA repair targeted therapies
    Stover, EH; Konstantinopoulos, PA; Matulonis, UA
  • DNA-Repair defects and olaparib in metastatic prostate cancer
    Mateo, J; Carreira, S; Sandhu, S
  • PROfound: phase 3 study of olaparib versus enzalutamide or abiraterone for metastatic castration-resistant prostate cancer (mCRPC) with homologous recombination repair (HRR) gene alterations
    Hussain, M; Mateo, J; Fizazi, K
  • PARP inhibitors in metastatic prostate cancer: evidence to date
    Nizialek, E; Antonarakis, ES
  • A prospective correlation of tissue histopathology with nucleic acid yield in metastatic castration-resistant prostate cancer biopsy specimens
    Jimenez, RE; Atwell, TD; Sicotte, H
  • Germline and somatic mutations in prostate cancer for the clinician
    Cheng, HH; Sokolova, AO; Schaeffer, EM; Small, EJ; Higano, CS
  • A pilot study of clinical targeted next generation sequencing for prostate cancer: consequences for treatment and genetic counseling
    Cheng, HH; Klemfuss, N; Montgomery, B
  • Plasma AR and abiraterone-resistant prostate cancer
    Romanel, A; Tandefelt, DG; Conteduca, V
  • Germline genetic testing in advanced prostate cancer; practices and barriers: survey results from the germline genetics working group of the Prostate Cancer Clinical Trials Consortium
    Paller, CJ; Antonarakis, ES; Beer, TM
  • Projecting the supply and demand for certified genetic counselors: a workforce study
    Hoskovec, JM; Benett, RL; Carey, ME
  • Evaluation of a streamlined oncologist-led BRCA mutation testing and counseling model for patients with ovarian cancer
    Colombo, N; Huang, G; Scambia, G
  • Identification of genetic counseling service delivery models in practice: a report from the NSGC service delivery model task force
    Cohen, SA; Marvin, ML; Riley, BD
  • Expanding access to BRCA1/2 genetic counseling with telephone delivery: a cluster randomized trial
    Kinney, AY; Butler, KM; Schwartz, MD
  • Exploring barriers to payer utilization of genetic counselors
    Doyle, N; Cirino, A; Trivedi, A; Flynn, M
  • Analysis of reimbursement of genetic counseling services at a single institution in a state requiring licensure
    Leonhard, JR; Munson, PJ; Flanagan, JD
  • Availability and payer coverage of BRCA1/2 tests and gene panels
    Clain, E; Trosman, JR; Douglas, MP; Weldon, CB; Phillips, KA
  • Genetics/genomics education for nongenetic health professionals: a systematic literature review
    Talwar, D; Tung-Sung, T; Foster, M; Xu, L; Lai-shin, C
  • Pretest genetic counseling services for hereditary breast and ovarian cancer delivered by non-genetics professionals in the State of Florida
    Vadaparampil, ST; Sherr, CL; Cragun, D; Malo, TL; Pal, T
  • Consumer awareness and attitudes about insurance discrimination post enactment of the Genetic Information Non-discrimination Act
    Allain, DC; Friedman, S; Senter, L; Nekhlyudov, L
  • Barriers in identification and referral to genetic counseling for familial cancer risk: the perspective of genetic service providers
    Rolnick, S; Rahm, AK; Jackson, JM
  • Barriers to participating in genetic counselling and BRCA testing during primary treatment for breast cancer
    Schlich-Bakker, KJ; Kroode, HFJT; Wárlám-Rodenhuis, CC; Bout, JVD; Ausems, MGEM
  • A descriptive study of UK cancer genetics services: an emerging clinical response to the new genetics
    Wonderling, D; Hopwood, P; Cull, A
  • Early use of clinical BRCA1/2 testing: associations with race and breast cancer risk
    Armstrong, K; Weber, B; Stopfer, G
  • What hinders minority ethnic access to cancer genetics services and what may help?
    Allford, A; Qureshi, N; Barwell, J; Lewis, C; Kai, J
  • Psychosocial factors predicting BRCA1/BRCA2 testing decisions in members of hereditary breast and ovarian cancer families
    Biesecker, BB; Ishibe, N; Hadley, DW
  • Individualized medicine enabled by genomics in Saudi Arabia
    Abu-Elmagd, M; Assidi, M; Schulten, HJ
  • Familial/inherited cancer syndrome: a focus on the highly consanguineous Arab population
    AlHarthi, FS; Qari, A; Edress, A; Abedalthagafi, M
  • Oncologist uptake of comprehensive genomic profile guided targeted therapy
    Nesline, MK; DePietro, P; Dy, GK
  • Molecular Tumor Boards: current practice and future needs
    van der Velden, DL; van Herpen, CML; van Laarhoven, HWM
  • Prostate cancer registries: current status and future directions
    Gandaglia, G; Bray, F; Cooperberg, MR
  • Prostate cancer in Asia: design of a patient registry to inform real-world treatments, outcomes, and quality of life
    Liu, Y; Uemura, H; Dingwei, Ye
  • United in Fight against prostate cancer registry (UFO): first results from a large, multi-center, prospective, longitudinal cohort study in Asia
    Uemura, H; D, Ye; Kanesvaran, R
  • Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients
    Zehir, A; Benayed, R; Shah, RH
  • Circulating tumor DNA genomics correlate with resistance to abiraterone and enzalutamide in prostate cancer
    Annala, M; Vandekerkhove, G; Khalaf, D
  • Pembrolizumab for treatment-refractory metastatic castration-resistant prostate cancer: multicohort, open-label phase II KEYNOTE-199 study
    Antonarakis, ES; Piulats, JM; Gross-Goupil, M
  • Microsatellite instability in prostate cancer and response to immune checkpoint blockade
    Abida, W; Cheng, ML; Armenia, J
  • TOPARP-B: A phase II randomized trial of the poly(ADP)-ribose polymerase (PARP) inhibitor olaparib for metastatic castration resistant prostate cancers (mCRPC) with DNA damage repair (DDR) alterations
    Mateo, J; Porta, N; McGovern, UB
  • Phase II study of niraparib in patients with metastatic castration-resistant prostate cancer (mCRPC) and biallelic DNA-repair gene defects (DRD): Preliminary results of GALAHAD
    Smith, MR; Sandhu, SK; Kelly, WK
  • Targeting DNA repair with combination veliparib (ABT-888) and temozolomide in patients with metastatic castration-resistant prostate cancer
    Hussain, M; Carducci, M; Slovin, S
  • Targeting androgen receptor and DNA repair in metastatic castration-resistant prostate cancer: results from NCI 9012
    Hussain, M; Daignault- Newton, S; Teardowski, PW
  • Olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a randomized, double-blind, placebo-controlled, phase 2 trial
    Clarke, N; Wiechno, P; Alekseev, B